Interestingly, results indicated that CD8A expression levels were inversely correlated with the IC50 of different antitumor agents to tumor cell lines, including several previously reported drugs; aurora kinase (AURK) inhibitor: GSK-1070916 (Hardwicke et al., 2009), 3-phosphoinositide-dependent protein kinase-1 (PDK-1) inhibitor: BX-912 (Bai et al., 2021), and nuclear factor kappa B inhibitor: BMS345541 (Li et al., 2019). The gene discussed is CD8A; the disease is neoplasm.